Physician profile
Eunice Lee
NPI 1740454032
$4,949.58
in general payments reported to CMS, 2019-2025
27 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $168 · 2021: $661 · 2022: $819 · 2023: $691 · 2024: $1,144 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,919.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $912.03 | 2021-2025 | Simbrinza, Clareon, Rhopressa |
| Abbvie INC. | $810.91 | 2022-2025 | |
| Oyster Point Pharma, INC. | $455.16 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $392.65 | 2022-2025 | Envista Mx60 Iol, Miebo, Vyzulta |
| Allergan, INC. | $301.65 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $293.80 | 2021-2022 | |
| Harrow Eye, LLC | $259.15 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $223.88 | 2019-2024 | Cequa, Xelpros |
| Kala Pharmaceuticals, INC. | $181.68 | 2019-2022 | |
| Dompe US, INC. | $173.74 | 2021-2025 | Oxervate |
| Amgen INC. | $113.74 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $102.82 | 2024-2025 | Xdemvy |
| New World Medical,INC. | $102.30 | 2022-2024 | Clearpath, Streamline, Ahmed Glaucoma Valve |
| Aerie Pharmaceuticals, INC. | $96.31 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $90.82 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $82.79 | 2019-2023 | Omni Surgical System |
| Novartis Pharmaceuticals Corporation | $79.78 | 2019-2023 | |
| Thea Pharma INC. | $63.02 | 2023-2025 | Iyuzeh |
| Shire North American Group INC | $44.43 | 2019 | |
| Ocular Therapeutix, INC. | $36.59 | 2023-2024 | Dextenza |
| Eyevance Pharmaceuticals LLC | $31.05 | 2019-2020 | |
| Biotissue Holdings INC. | $20.73 | 2019 | |
| Rxsight INC | $17.64 | 2024 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Abb Con-Cise Optical Group LLC | $17.05 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $16.55 | 2023 | Tecnis Iol |
| Teva Pharmaceuticals USA, INC. | $14.96 | 2019 | |
| Ethicon US, LLC | $14.35 | 2025 | Contour |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunice Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.